Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-01-05Clinical Trial Update: Common Factors Group Psychotherapy for General Mental Health Concerns [NA]
A clinical trial evaluating common factors group psychotherapy for general mental health concerns has been withdrawn, with target conditions…
-
CLINICAL_TRIALS withdrawal · 2024-05-08Clinical Trial Update: Cognitive Behavioral Therapy (CBT) for Late Life Anxiety [NA]
A clinical trial evaluating Cognitive Behavioral Therapy for Generalized Anxiety Disorder in older adults has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-03-24Clinical Trial Update: Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study [Phase 3]
An 8-week phase 3 pilot trial of cannabinoids for anxiety disorders was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-24Clinical Trial Update: Worry Exposure for Generalized Anxiety Disorder [NA]
The clinical trial 'Worry Exposure for Generalized Anxiety Disorder' sponsored by the University of Texas at Austin has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-17Clinical Trial Update: Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men [Phase 1, Phase 2]
A Phase 1/2 clinical trial of a mobile phone app for depressive symptoms and generalized anxiety in young men who have sex with men was with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects [Phase 1]
Phase 1 study to estimate the effect of PD 0332334 on lithium pharmacokinetics in healthy subjects has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-12-03Clinical Trial Update: 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD) [Phase 3]
Pfizer's Phase 3 open-label safety study of PD-0332334 in elderly patients with Generalized Anxiety Disorder has been withdrawn.